10-K: RxSight Reports Mixed 2025 Results Amid Sales Reorganization

RxSight, Inc. reported a 3.9% decrease in total sales for 2025 to $134.5 million, driven by slower adoption of its Light Delivery Devices, despite an increase in Light Adjustable Lens sales and improved gross margin.

Summary

• Total sales decreased by 3.9% to $134.5 million in 2025 from $139.9 million in 2024.
• Light Delivery Device (LDD) sales decreased by 142 units (47%) in 2025 compared to 2024, attributed to slower adoption by practices and doctors.
• Light Adjustable Lens (LAL) sales increased by 11,560 units (12%) in 2025 compared to 2024, driven by a larger LDD installed base.
• Gross profit increased by $4.1 million (4.1%) to $103.0 million in 2025.
• Gross margin improved to 76.6% in 2025 from 70.7% in 2024, primarily due to a favorable product mix with LAL revenue comprising 80% of total revenue (up from 69% in 2024).
• Operating expenses increased by 11.3% to $151.2 million in 2025.
• Selling, general and administrative (SG&A) expenses increased by 11.1% to $112.7 million, driven by higher selling and marketing costs, personnel costs, stock-based compensation, marketing study costs, and new customer acquisition costs.
• Research and development (R&D) expenses increased by 12.2% to $38.5 million, mainly due to R&D activities and personnel costs.
• Net loss increased by 41.8% to $38.9 million in 2025 from $27.5 million in 2024.
• The company had an accumulated deficit of $661.0 million as of December 31, 2025.
• The installed base of LDDs reached 1,134 as of December 31, 2025, and approximately 300,000 LALs have been implanted since inception through December 31, 2025.
• The U.S. commercial organization was realigned into a single Customer Success Organization to better support existing customers and drive long-term LAL utilization growth.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a mixed report. While gross margin improved and LAL sales increased, the significant decline in LDD sales and widening net losses indicate challenges in market penetration and achieving overall profitability. The ongoing legal proceedings add further uncertainty.

Positives

• Gross profit increased by $4.1 million (4.1%) to $103.0 million in 2025.
• Gross margin improved significantly to 76.6% in 2025 from 70.7% in 2024, driven by a favorable product mix with higher-margin LAL sales.
• LAL sales volume increased by 11,560 units (12%) in 2025, indicating continued adoption of the core product.
• The installed base of Light Delivery Devices (LDDs) grew to 1,134 by December 31, 2025, providing a foundation for future LAL sales.
• The company believes its current cash, cash equivalents, and short-term investments of $228.1 million are sufficient to fund operations for at least the next 12 months.
• FDA clinical trials showed superior visual outcomes for LAL patients, with 70% achieving 20/20 or better uncorrected visual acuity, significantly higher than competitor IOLs.
• LAL patients do not experience increased incidence of glare or halos, which are common side effects with other premium IOLs.
• A 2025 customer survey indicated 90% of respondents thought the RxSight system delivered the highest quality vision and 96% would recommend the LAL.
• The Post Approval Study (PAS) for LAL was accepted by the FDA as of February 7, 2025, fulfilling Premarket Approval (PMA) requirements.
• The PAS showed 82.5% of LAL eyes achieved 20/20 or better uncorrected distance visual acuity, compared to 50.6% of control eyes.
• The compact LDD received FDA approval in January 2023, Canada approval in September 2024, and South Korea approval in February 2025, indicating successful international regulatory expansion for the device.

Negatives

• Total sales decreased by $5.5 million (3.9%) in 2025 compared to 2024.
• LDD sales decreased by 142 units (47%) in 2025, indicating slower adoption of the core technology by practices and doctors.
• Net loss increased significantly by 41.8% to $38.9 million in 2025 from $27.5 million in 2024.
• Operating losses increased to $48.2 million in 2025 from $36.9 million in 2024.
• Accumulated deficit reached $661.0 million as of December 31, 2025.
• Selling, general and administrative expenses increased by 11.1% to $112.7 million, contributing to higher operating losses.
• Research and development expenses increased by 12.2% to $38.5 million, further impacting profitability.
• The company has a history of net losses and negative cash flows from operations since inception and expects to continue incurring losses in the near future.
• Interest and other income, net, decreased by $0.2 million in 2025 due to lower interest rates on investment balances.

Risks

• Failure to effectively train the sales force, increase sales and marketing capabilities, or develop broad brand awareness in a cost-effective manner could impede growth.
• Continued net losses and inability to sustain profitability if achieved.
• Need to raise additional capital, which may not be available on acceptable terms or at all, leading to potential dilution or restrictive debt covenants.
• Dependence on the RxSight system; failure to successfully market and sell it would significantly harm business prospects.
• Intense competition in the surgical ophthalmology market from larger, well-capitalized companies like Alcon and Johnson & Johnson.
• Patient requirements to wear UV protective glasses for approximately 4-5 weeks post-surgery and attend 2-3 additional clinic visits may impact LAL market acceptance.
• Risks associated with international expansion, including differing regulatory requirements, compliance difficulties, economic/political instability, and currency fluctuations.
• Global economic, political, and market conditions (e.g., U.S. credit rating downgrades, inflation, conflicts in Eastern Europe/Middle East) may adversely affect business.
• Reliance on single and sole source suppliers for critical components, making the company vulnerable to supply disruptions and price fluctuations.
• Inability to obtain, maintain, protect, and enforce intellectual property rights, or if the scope of protection is insufficient, could hinder competition.
• Risk of trade secrets and proprietary information being misappropriated or disclosed.
• Potential for intellectual property litigation or administrative proceedings, which could be costly and divert management attention.
• Inadequate patent terms to protect competitive position for a sufficient duration.
• Risks associated with the use of open-source software, potentially requiring disclosure of proprietary source code.
• Failure to obtain and maintain necessary regulatory clearances or approvals for products, or delays in future product approvals.
• Results of earlier clinical studies may not be predictive of future results, and planned studies may not establish adequate safety or efficacy.
• Potential for defects or failures associated with products leading to recalls, safety alerts, or litigation.
• Risks of unauthorized third parties accessing devices or systems, leading to cybersecurity breaches, data loss, or misuse.
• Expenditure of limited resources on less profitable products or indications.
• Inability to develop, license, or acquire new products or enhance existing ones to keep pace with rapidly changing technology.
• Uncertainties in market size estimates for current and future products.
• Changes in state regulations regarding optometry practice, insurance coverage, government reimbursement rates, or medical malpractice insurance could affect product adoption.
• Healthcare reform initiatives and other administrative/legislative proposals could adversely affect business by limiting pricing or reimbursement.
• Fluctuations in quarterly and annual results due to seasonality and other factors.
• Difficulties in managing organizational growth, including expanding sales and marketing.
• Limitations on the ability to use net operating loss carryforwards and other tax attributes due to ownership changes.
• Potential for successful assertion by taxing authorities that the company should have collected sales and use, VAT, or similar taxes.
• Dependence on attracting and retaining highly skilled executive officers and employees.
• Litigation and other legal proceedings, including existing securities class action and shareholder derivative lawsuits, could be costly and divert management attention.
• Business disruptions (e.g., natural disasters, power shortages) could harm revenue and increase costs.
• Inability to accurately forecast customer demand and manage inventory, leading to obsolescence or supply shortages.
• Inadequate funding for the FDA and other government agencies could hinder their ability to hire and retain key personnel, preventing timely product development or commercialization.
• Global operations expose the company to numerous and sometimes conflicting legal and regulatory requirements, including anti-bribery and anti-corruption laws, with potential for substantial penalties and prosecution.

Future Outlook

The company expects revenue to increase in absolute dollars as it expands its sales organization and territories, adds customers, expands the base of doctors trained to use its products, and increases awareness. It anticipates continued net losses and negative cash flows from operations in the near future due to ongoing investments in business and products. While not anticipating the need for additional capital to reach profitability, the company may opportunistically seek to raise capital under advantageous circumstances to support expansion and pursue other business opportunities. Current manufacturing capacity is believed to be sufficient for the next 12 months, and the company expects to realize operating leverage and potential margin improvement through increased scale efficiencies and supply chain optimization. Research and development will continue to focus on system enhancements, expanding indications, and reducing manufacturing costs.

Management Comments

• "We believe our RxSight system provides doctors and patients increased confidence and peace of mind by eliminating the high-stakes preoperative guesswork common to competitive premium IOLs and allowing patients to iterate their final vision characteristics with customized post-surgical adjustments."
• "We believe that the premium cataract surgery market remains underpenetrated due to both doctors reluctance to recommend premium IOL offerings to the full universe of eligible patients and patients confusion in assessing the trade-offs associated with the wide range of commercially available premium IOL offerings."
• "We believe our RxSight system offers doctors and patients a significantly more reliable approach that can consistently deliver optimal, fully customized visual outcomes with few compromises, ultimately driving broad adoption and establishing it as the standard of care for premium cataract procedures."
• "We plan to grow our business primarily by expanding the size of our LDD installed base and driving increased utilization of our LAL through heightened awareness of the superior clinical outcomes our RxSight system provides patients."
• "We expect cost of sales to increase in absolute dollars as our revenue grows and higher volume of products are sold."
• "We expect selling, general and administrative expenses to continue to expand as we increase our research and development activities, build out our marketing, sales and clinical teams in the U.S. and outside the U.S., and otherwise grow our business."
• "We expect to maintain our focus on research and development spending as we seek to improve clinical outcomes, improve customer experience, expand our indications for use, reduce manufacturing costs and support lifecycle management."
• "Although, based on our current planned operations, we do not anticipate the need to raise additional capital or incur additional debt in order to reach profit from operations... we may opportunistically raise capital under advantageous circumstances from time to time to support the expansion of our sales and operations in the U.S. and internationally and to pursue other business opportunities."
• "We believe we have meritorious defenses, vehemently deny the allegations and intend to defend the case vigorously." (Regarding legal proceedings)

Industry Context

StockSavvy.ai notes that RxSight operates in the highly competitive surgical ophthalmology market, dominated by large players like Alcon and Johnson & Johnson, who collectively hold approximately 75% of the U.S. premium cataract surgery market. The company's 'razor and razor blade' business model, focusing on LDD installation to drive LAL sales, is a common strategy in medical device industries for recurring revenue. The reported growth in LAL sales and installed LDD base, despite a decline in new LDD sales, suggests a shift towards maximizing utilization within its existing customer base, a critical factor for profitability in this model. The company's emphasis on superior clinical outcomes and post-surgical adjustability aims to differentiate it in a market where patient expectations for glasses-free vision are high but often unmet by conventional premium IOLs.

Comparison to Industry Standards

• In its FDA clinical trial, 70% of LAL patients achieved 20/20 or better uncorrected visual acuity without glasses, which is significantly higher than reported in similar trials for competitor premium IOLs such as Alcon's Acrysof Toric (38.4%) and J&J's Tecnis Toric (43.6%).
• LAL patients do not experience increased incidence of glare or halos, which are common with multifocal IOLs. In contrast, Alcon Panoptix reported 48.8% of subjects bothered by halos postoperatively, and J&J Symfony reported 59.2%.
• In a recent Phase IV commercial study, over 90% of LAL patients who chose to optimize vision with both eyes achieved 20/25 or better distance vision and could read 5-point font without glasses, which is significantly higher than alternative IOLs.
• The premium IOL market in the U.S. represented about 21% of all cataract procedures in 2025, generating approximately $860 million in revenue, projected to grow at an 8.0% CAGR by 2030. Globally, premium IOL revenue was approximately $2.6 billion in 2025, expected to grow at an 11% CAGR through 2030. RxSight's LAL sales growth of 12% in 2025 indicates it is participating in this market expansion, though the decline in LDD sales suggests challenges in new market penetration compared to the overall market growth.

Management Changes

Corporate Governance

Legal Proceedings

• **Securities Class Actions**: On July 22, 2025, a putative securities class action complaint (Makaveev v. RxSight, Inc., et al.) was filed, followed by a related complaint on September 16, 2025 (Gemesi v. RxSight, Inc., et al.). These were consolidated on October 6, 2025, alleging materially false and misleading statements and omitted material adverse facts regarding product demand and financial guidance. A consolidated, amended complaint was filed on December 12, 2025, and defendants' motion to dismiss was filed on February 13, 2026. Plaintiffs seek unspecified compensatory and punitive damages, and legal costs.
• **Shareholder Derivative Actions**: On August 18, 2025, a shareholder derivative action (Swift v. Kurtz, et al.) was filed, followed by a related action on October 10, 2025 (Yost v. Kurtz, et al.). These were consolidated on November 13, 2025, and stayed until the final resolution of the Securities Class Actions. The complaints allege false and misleading statements, omitted material adverse facts regarding declining sales and financial guidance, lack of internal controls, violations of Section 14(a) of the Exchange Act, breaches of fiduciary duties, aiding and abetting, unjust enrichment, and waste of corporate assets. Plaintiffs seek unspecified damages on behalf of the company, declaratory relief, a constructive trust, punitive damages, and legal costs.

Stakeholder Impact

• **Shareholders**: Face potential dilution from future equity offerings, stock price volatility due to market conditions and litigation, and limited returns as no cash dividends are anticipated. The ongoing securities class action and shareholder derivative lawsuits could result in substantial costs and negatively impact share value.
• **Employees**: Experience management changes with a new CFO and a CCO promotion. Benefit from stock-based compensation plans and 401(k) matching contributions. The organizational realignment aims to improve support and utilization, potentially impacting roles and responsibilities.
• **Customers (Ophthalmic Practices, ASCs)**: Will continue to receive training and support from the newly formed Customer Success Organization. They face a significant upfront investment for LDDs, but LAL procedures offer potential for increased practice revenue and profit margins. Changes in reimbursement policies could affect their ability to offer the RxSight system profitably.
• **Patients**: Benefit from the RxSight system's promise of customized vision correction, superior visual outcomes, and low incidence of side effects like glare and halos. However, they must comply with wearing UV protective glasses and attend additional clinic visits, which could be a barrier to adoption for some.
• **Suppliers**: The company's reliance on third-party, including single and sole source, suppliers exposes them to risks of supply disruptions, price fluctuations, and extended global lead times for raw materials and components.

Next Steps

• Expand sales organization and sales territories.
• Add new customers and expand the base of doctors trained to use products.
• Expand awareness of products with new and existing customers.
• Drive increased utilization of LALs through heightened awareness of superior clinical outcomes.
• Invest in RxSight system enhancements to improve clinical outcomes, customer experience, expand indications for use, reduce manufacturing costs, and support lifecycle management.
• Undertake additional clinical studies to expand the existing body of evidence related to safety and effectiveness.
• May acquire or invest in additional businesses, products, or technologies.
• Accelerate marketing initiatives and professional education.
• Selectively pursue commercial expansion outside the U.S., prioritizing markets with significant potential growth opportunities.
• Seek new regulatory approvals in large cataract markets with more complex regulatory environments.
• Continue to defend against securities class action and shareholder derivative lawsuits.

Key Dates

Recommendation

The company shows strong clinical results and growing LAL utilization, indicating a valuable core product. However, the significant decline in LDD sales, widening net losses, and ongoing legal challenges create considerable uncertainty. The strategic realignment and focus on existing customer utilization are positive steps, but the path to sustained profitability remains unclear. A 'Hold' recommendation is appropriate as investors await clearer signs of successful market penetration and financial improvement, while monitoring the outcome of litigation.

Keywords

Cataract surgery, Light Adjustable Lens, LAL, Light Delivery Device, LDD, Intraocular lens, IOL, Ophthalmology, Medical technology, Refractive error correction, FDA approval, Premium IOL market, Medical device, RxSight system, Financial results 2025, SEC 10-K